[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555084":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":45,"responsibleParty":76,"collaborators":80,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":86,"sex":92,"minAge":93,"maxAge":94,"enrollmentInfo":95,"targetDuration":31,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":48,"whyStopped":31,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"First People's Hospital of Shenyang","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Daphnetin","EXPERIMENTAL","oral Daphnetin Capsule three capsules\u002Ftid for up to six months.",[13],"Drug: Daphnetin Capsule",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","oral Placebo (Daphnetin Capsule simulants) three capsules\u002Ftid for up to six months.",[19],"Drug: Placebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Daphnetin Capsule","Daphnetin, chemically known as 7,8-dihydroxycoumarin, also known as ZuShiMaJiaSu, is a class of coumarin derivatives derived from different Daphnetin genus plant .",[9],[27],"7,8-dihydroxycoumarin",{"type":22,"name":15,"description":29,"armGroupLabels":30,"otherNames":31},"The placebo is a Daphnetin Capsule simulants",[15],null,[33],{"name":34,"affiliation":35,"role":36},"Yi Sui, MD PhD","The Fourth People's Hospital of Shenyang, China Medical University","PRINCIPAL_INVESTIGATOR",[38,42],{"name":34,"role":39,"phone":40,"phoneExt":31,"email":41},"CONTACT","+86 24 86861329","jakeyisui@icloud.com",{"name":43,"role":39,"phone":40,"phoneExt":31,"email":44},"Mingming Dong, MD","dongming_ming@126.com",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Shenyang First People's Hospital","RECRUITING","Shenyang","Liaoning","110041","China","CN",{"type":55,"coordinates":56},"Point",[57,58],123.43278,41.79222,{"lat":58,"lon":57},[61,65,68,69,71,74],{"name":62,"role":39,"phone":63,"phoneExt":31,"email":64},"Li Li, MD PhD","+86 24 31956000","lily720823@163.com",{"name":66,"role":39,"phone":63,"phoneExt":31,"email":67},"Xinze Guo, MD","176953982@qq.com",{"name":62,"role":36,"phone":31,"phoneExt":31,"email":31},{"name":70,"role":36,"phone":31,"phoneExt":31,"email":31},"Wei Bian, MD",{"name":72,"role":73,"phone":31,"phoneExt":31,"email":31},"Hong Wang","SUB_INVESTIGATOR",{"name":75,"role":73,"phone":31,"phoneExt":31,"email":31},"Yang Zhao",{"type":36,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":79,"oldNameTitle":31,"oldOrganization":31},"Dr. Yi Sui","vice president","Fourth People's Hospital of Shenyang",[81],{"name":82,"class":83},"The Fourth People's Hospital of Shenyang","UNKNOWN","100555084","daphnetin-capsule-in-the-treatment-of-vascular-cognitive-impairment-without-dementia-100555084",false,"NCT06507488","Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia","Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia - A Randomized, Double-blind, Placebo-controlled Study","DISCO","Inclusion Criteria:\n\n1. Be 50-80 years of age (both ends included)\n2. Have a complaint of cognitive impairment involving memory and\u002For other cognitive domains that has persisted for at least 3 months\n3. Have a cognitive level that is neither normal nor demented according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Criteria ( DSM-V criteria）, a Montreal Cognitive Assessment (MoCA scale) score \\\u003C26 and ≥18, and a Clinical Dementia Rating (CDR) scale score of ≥0.5 in at least one domain and an overall CDR score ≤1\n4. Have a cognitive level that is neither normal nor demented according to DSM-V criteria, a MoCA scale score \\\u003C26 and ≥18, and a CDR scale score of ≥0.5 in at least one domain and an overall CDR score ≤1\n5. Voluntarily participate in this study and sign an informed consent form.\n\nExclusion Criteria:\n\n1. Previously diagnosed dementia; vascular cognitive impairment not associated with a condition other than dementia that may affect cognition\n2. Acute stroke event within 6 months\n3. Previously diagnosed hereditary or inflammatory small vessel disease\n4. Presence of congenital mental retardation and severe neurological or psychiatric disorders\n5. Illiteracy or severe visual or hearing impairment, severe aphasia, and other factors that may preclude cooperation with neuropsychological evaluation\n6. Associated depression (Hamilton Depression Scale score ≥ 17), or other unrelated serious mental illness (schizophrenia, bipolar disorder, or delirium)\n7. Combined severe cardiac, pulmonary, and renal insufficiency (creatinine \\> 2.0 mg\u002Fdl or 177 μ mol\u002FL), and severe hepatic impairment (aminotransferases more than 3 times normal)\n8. Alcoholism, drug addiction, or ongoing use of medications that affect cognitive assessment, such as tranquilizers, sleeping pills, puberty pills, and cholinergics\n9. Malignant tumors that have been clearly diagnosed, vital organ failure\n10. Those with bleeding tendency after surgery\n11. Pregnant and lactating women are prohibited\n12. Severe hypertension (Systolic Blood Pressure(SBP)≥160mmHg and\u002For Diastolic Blood Pressure(DBP)≥110mmHg) is prohibited\n13. Previous allergy or intolerance to the ingredients of Reserpine\n14. The subject does not have a stable and reliable caregiver or the caregiver is unable to assist the subject in participating in the study\n15. Patients who have participated in other interventional clinical studies within the last 3 months or are currently participating in other interventional clinical studies.","ALL","50 Years","80 Years",{"count":96,"type":97},206,"ESTIMATED","INTERVENTIONAL",[100],"NA","The purpose of this clinical trial is to understand and evaluate the clinical efficacy and safety of Daphnetin Capsule in patients with vascular cognitive impairment. Changes in the Vascular Dementia Assessment Scale-cog(VADAS-cog) at 6 months were evaluated. Although Daphnetin has a dual neurovascular protective effect, however, there is still a lack of relevant high-quality studies on its role in patients with vascular cognitive impairment, especially in patients with vascular cognitive impairment in non-dementia (VCI-ND), whether it has a role in improving cognitive status needs to be urgently explored in high-quality clinical studies. Researchers are comparing Daphnetin to placebo (a drug-free analog) to see if Daphnetin is effective in treating vascular cognitive impairment. Participants will take either Daphnetin or placebo daily for six months, with follow-up visits every three months and completion of a case report form.",[103],"Cerebrovascular Disorders",[105,9,106,107],"Vascular Cognitive Impairment No Dementia","Effectiveness","safety","2025-08-21",{"date":110,"type":111},"2025-08-28","ACTUAL",{"date":113,"type":111},"2025-07-07",{"date":115,"type":97},"2026-04-30",{"name":5,"class":6},1]